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Inflammatory Bowel Diseases (IBD), whose denomination comprehends Crohn’s Disease
(CD) and Ulcerative Colitis (UC), are intestinal chronic diseases that often require lifelong
medical therapy. In the last two decades monoclonal antibodies against the cytokine TNF
have become integral parts in the treatment of IBD patients, however there are unwanted
side-effects and one third of patients show primary non-response while another subgroup
loses response over time. Finding novel drugs which could act as therapies against
precise pro-inflammatory molecular targets to avoid unwanted systemic side effects and
additionally the process of immunization, represents an important aim for subsequent
therapeutic approaches. Oligonucleotide based therapies represent a promising novel
concept for the treatment of IBD. The molecular action of oligonucleotides ranges from
inhibition of the translational process of mRNA transcripts of pro-inflammatory molecules,
to mimicking bacterial DNA which can activate cellular targets for immunomodulation.
Alicaforsen, selectively targets ICAM-1 mRNA. ICAM-1 is an adhesion molecule which
is upregulated on endothelial cells during IBD, thereby mediating the adhesion and
migration of leucocytes from blood to sites of active inflammation. In CD parenteral
application of alicaforsen did not show therapeutic efficacy in phase II trials, but it
demonstrated an improved efficacy as a topical enema in distal UC. Topical application
of alicaforsen might represent a therapeutic perspective for refractory pouchitis as
well. SMAD7 is a protein that inhibits the signaling of TGFβ, which is the mainstay of
a regulatory counterpart in cellular immune responses. An antisense oligonucleotide
against SMAD7 mRNA (mongersen) demonstrated pre-clinical and phase II efficacy in
CD, but a phase III clinical trial was stopped due to lack of efficacy. Cobitolimod is
a single strand oligonucleotide, which mimics bacterial DNA as its CpG dinucleotide
sequences can be recognized by the Toll-like receptor 9 on different immune cells
thereby causing induction of different cytokines, for example IL10 and IFNα. Topical
application of cobitolimod was studied in UC patients. We will also discuss two other
novel oligonucleotides which act on the GATA3 transcription factor (SB012) and on
carbohydrate sulfotransferase 15 (STNM01), which could both represent novel promising
therapeutic options for the treatment of UC.
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Scarozza et al. Oligonucleotide Based Therapies
INTRODUCTION
Inflammatory bowel diseases (IBD) are chronic inflammatory
disorders of the intestine whose phenotypic spectrum mainly
comprehends Crohn’s disease (CD) and ulcerative colitis (UC).
IBD are characterized by a chronic disease course with the
alternation of active and quiescent phases, thereby requiring
continuous follow up and management by health care systems
(Maaser et al., 2019). In the last 20 years, there has been an
increase in the prevalence of IBD from a percentage of 0.3–
0.5% in North America and similarly in Northern Europe,
Western Europe, and Oceania (Kaplan and Ng, 2017). Moreover,
a profound rise in incidence was described in Asia and Latin
America (Ng et al., 2018).
IBD patients often require treatment with
immunomodulatory drugs such as thiopurines, methotrexate;
biological drugs, like anti-Tumor Necrosing Factor (anti-TNF),
anti-adhesion, or anti-interleukin 12/23p40 (IL12/23p40)
antibodies and lately also Janus Kinase Inhibitors (JAK-
inhibitors). These different substance classes have become
integral parts in the treatment of IBD patients; however there are
unwanted, sometimes even severe side effects and over one third
of patients show primary non-response while another subgroup
of patients loses response over time (Roda et al., 2016). There
is therefore the dire need for novel efficacious therapies with a
favorable safety profile. Oligonucleotides represent an emerging
substance class of targeted therapies with only limited systemic
exposure to the drug, giving hope for a novel and rather safe
treatment modality in IBD.
The molecular mechanism of action of oligonucleotides
ranges from inhibition of the translational process of messenger
ribonucleic acid (mRNA) transcripts of pro-inflammatory
molecules, to mimicking bacterial deoxyribonucleic acid (DNA)
which can activate cellular targets for immunomodulation.
Antisense technology is based on two principal different
modes of action: activation of Ribonuclease H (RNase H)
or double-strand RNases. The activation of RNase H is
mediated by the recognition of the sense-antisense heterodimer,
after the binding of the single-strand oligonucleotide to the
complementary target mRNA (Crooke, 2004). The heterodimer
induces the activation of the RNase H enzyme, which inhibits the
expression of the target mRNA (Aboul-Fadl, 2005). The second
antisense mechanism is linked to the action of double-strand
RNases which are activated by silence RNA (siRNA) molecules
that are characterized by a double-strand oligonucleotide formed
by a sense and an antisense RNA strand. After entering the cell,
the antisense RNA recognizes the target cytoplasmic mRNA,
forming a sense-antisense duplex, that is finally degraded by
endogenous double-strand RNases (Crooke, 2004).
For the last 20 years, antisense technology has been
improved in various fields of medical research. In 1999 the
European Agency for the Evaluation of Medical Products
(EMEA) approved Fomivirsen, as the first therapeutically
used antisense oligonucleotide, developed for the treatment
of Cytomegalovirus (CMV) retinitis. In the meantime many
more oligonucleotide based substances have been tested in
respective trials or already entered clinical practice: Macugen
to treat age-related macular degeneration; Mipomersen for
homozygous familial hypercholesterolemia; Eteplirsen for
Duchenne muscular dystrophy; Defibrotide for severe hepatic
veno-occlusive disease; and Nusinersen for the treatment
of infants with types 1, 2, and 3 spinal muscular atrophy
(Stein and Castanotto, 2017).
This review focuses on pharmacodynamics and clinical
perspectives of oligonucleotide based therapeutics so far studied
for the treatment of IBD. (Supplementary Material).
ALICAFORSEN
Active inflammation in IBD is characterized by overexpression
of adhesion molecules on endothelial cells that are centrally
involved in mediating the gut homing of leukocytes. Inhibition
of migration has become one of the established therapeutic
approaches in IBD, with approval of the alpha4beta7 antibody
vedolizumab for treatment of both IBD entities and ongoing
clinical trials for many more therapeutic targets of the homing
process (Sands, 2017; Zundler and Neurath, 2017). Intercellular
Cell Adhesion Molecule-1 (ICAM1) is an adhesion molecule
derived from the immunoglobulin superfamily acting as a ligand
for the integrins expressed by leukocytes and represents one
of the novel targets of antisense oligonucleotide (ASO) based
therapeutic strategies (Mosli et al., 2014; Sands, 2017).
ICAM1 is overexpressed by endothelial cells during active
disease in CD patients and its presence is thus diminished
during remission. It was furthermore shown, that in UC patients
the expression of ICAM1 in colonic tissue is higher than in
respective controls (Jones et al., 1995; Vainer and Nielsen, 2000;
Rivera-Nieves et al., 2008).
Preclinical studies have figured out the efficacy of a
monoclonal antibody against ICAM1 administered topically in
the experimental dextran sulfate sodium (DSS) murine model
of colitis, which led to the reduction of mucosal inflammation
(Hamamoto et al., 1999). When combined with anti-Vascular
Cell AdhesionMolecule-1 (anti-VCAM1) or anti-alpha4 integrin
antibodies, the ICAM1 antibody similarly exerted a positive effect
on reducing the inflammatory response in a murine model of
ileitis (Burns et al., 2001).
Alicaforsen is a 20-base phosphorothioate ASO that
hybridizes the mRNA of ICAM1 and induces the hydrolysis
of the DNA-RNA complex by an RNAse enzyme (Gewirtz
and Sitaraman, 2001). A randomized trial of ISIS 2302, an
ASO to ICAM1, was conducted in patients affected by severe
rheumatoid arthritis, without evidence of significant efficacy,
but with a good safety profile (Maksymowych et al., 2002).
A pivotal phase I dose ranging trial conducted on healthy
volunteers who intravenously received the ICAM1 ASO, showed
good tolerance to the drug, with reproducible plasma levels
and limited side effects (dose-related increase in activated
partial thromboplastin time, clinical insignificant increases
in complement factor C3a) at the time of the peak plasma
concentration, without occurrence of associated clinical
symptoms (Glover et al., 1997).
A dose ranging pharmacokinetic trial of high-dose alicaforsen
randomized 22 patients with active CD to three alicaforsen
treatment groups: 250-, 300-, or 350-mg doses, infused
intravenously three times a week for 4 weeks. The authors
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evidenced a possible effectiveness of alicaforsen therapy in CD.
Clinical remission was evidenced in 41% of all treated subjects
and in 53% of those treated with more than three of the 12
infusions planned (Yacyshyn et al., 2002a).
A randomized trial of ISIS 2302, conducted in twenty CD
patients, allocated to receive one of three different doses of
this drug (0.5, 1, or 2 mg/kg) or saline placebo, evidenced a
therapeutic success of the experimental drug, which was infused
intravenously in 13 doses over 26 days (Yacyshyn et al., 1998;
Reinisch et al., 2018). The remission rate after 1 month of therapy
was 47% (7/15) in patients treated with the investigated substance
and 20% (1/5) in patients treated with placebo. At the end of the
6 months follow up period, 5 of the 7 patients treated with the
investigated substance maintained clinical remission and 33% (5
of 15) successfully tapered concomitant corticosteroid treatment
(Yacyshyn et al., 1998).
These positive perspectives about the steroid sparing effect
of ISIS 2302 were not confirmed in a subsequent trial, which
primary endpoint was steroid-free remission at week 14. Here, 75
steroid refractory CD patients were randomized to four groups
of treatment with ISIS 2302 or to placebo. The study drug
was administered subcutaneously at four different dose-interval
regimens (0.5 mg/kg once daily for 2 days; 0.5 mg/kg five times
a week for 1 week; 0.5 mg/kg five times a week for 2 weeks
or 0.5 mg/kg five times a week for 4 weeks) (Schreiber et al.,
2001; Lobaton et al., 2014). Steroid-free remission at week 14
was registered in only 3.3% (2/60) of patients treated with ISIS
2302 and in none of the placebo patients (Schreiber et al., 2001;
Lobaton et al., 2014). This negative property to induce steroid-
free remission was also confirmed by another study (Yacyshyn
et al., 2002b). Here, 299 steroid-dependent CD patients were
randomized into three treatment arms: ISIS 2302 (2 mg/kg) given
intravenously three times a week for two weeks, vs. ISIS 2302
(2 mg/kg) given intravenously three times a week for 4 weeks,
compared to placebo application. Steroid free remission at week
14 was defined as the primary endpoint. It was reached by 20.2
and 21.2%, respectively in the ISIS 2302 arm with treatment
lasting 2 or 4 weeks compared to 18.8% in the placebo arm.
Therefore, no statistical significant difference regarding clinical
efficacy could be shown (Yacyshyn et al., 2002b).
The last clinical trial conducted in CD patients, which results
were published in 2007, confirmed the inefficacy of alicaforsen in
inducing clinical remission in CD patients. In this study, 331CD
patients were randomized to two treatment groups: alicaforsen
given intravenously, at a dosage of 100mg at the time of the
first infusion, followed by 300mg given three times a week for 4
weeks (n = 221) compared to placebo administration (n = 110).
The primary endpoint was clinical remission at week 12. No
statistical differences regarding clinical remission at week 12 were
evidenced between the two treatment groups (33.9% in the group
treated with alicaforsen vs. 34.5% in the placebo group; p= 0.89)
(Yacyshyn et al., 2007). These results have led to the halt of further
clinical studies of this compound in CD patients.
In UC, some clinical studies demonstrated efficacy of
alicaforsen in inducing clinical response and remission via topical
application. First, an effective induction of clinical response by
topical application of alicaforsen was evidenced by a randomized
multicenter trial conducted in 40 UC patients affected by mild
to moderate distal colitis, who were randomized to four dosing
cohorts of an alicaforsen enema (0.1, 0.5, 2, or 4 mg/ml) or
placebo, given once daily for 28 consecutive days (van Deventer
et al., 2004). This therapeutic procedure resulted in the induction
of clinical response in a dose-dependent way, with induction
of response in 70% of alicaforsen 4 mg/ml treated patients
compared to a placebo response of 28% at week 4, which
was statistically significant (p = 0.004). In the group treated
with alicaforsen at a dosage of 2 mg/ml, clinical response was
evidenced in 45% of treated patients (p = 0.201). During the
6 months clinical follow up period, half of the patients in
the placebo arm (4/8) required another medication or surgical
intervention, whereas none of the patients treated with the
highest dose of alicaforsen and two patients in the 2 mg/ml group
required treatment escalation (van Deventer et al., 2004).
A randomized controlled trial conducted in active UC
patients affected by mild to moderate left-sided colitis did
not lead to a significantly different clinical outcome between
the groups treated with topical application of the alicaforsen
enema compared to placebo administration. The patients were
randomized to five treatment arms: alicaforsen enema at a dosage
of 120mg daily for the first 10 days of 6 weeks of treatment
and then every other day thereafter; 240mg every other day
for 6 weeks; 240mg daily for the first 10 days of 6 weeks of
treatment and then every other day thereafter or 240mg daily for
6 weeks or placebo application. Primary endpoint was the Disease
Activity Index (DAI) score at week 6. No significant differences
were evidenced between the treatment arms and placebo (van
Deventer et al., 2006). All groups demonstrated a decrease in
the DAI score, but the best cohort response was identified in the
group treated with daily application of 240mg alicaforsen enema.
Clinical response at week 6 was 47% in the 240mg alicaforsen
arm and 33% in the placebo arm (p=N.S.). Despite no significant
differences identified for the primary endpoint clinical response,
this study demonstrated that patients treated with an alicaforsen
enema maintained an improved DAI score from week 18 to week
30 after commencement of therapy, compared to patients treated
with placebo. The decrease in the mean DAI score compared
to baseline was 51% at week 18 and 50% at week 30 in the
group treated with daily application of 240mg alicaforsen enema,
compared to 18% (p = 0.04) and 11% in the placebo arm
(p= 0.03) (van Deventer et al., 2006).
A subsequent randomized study was conducted in UC
patients affected by mild to moderate distal UC, which were
randomized to three treatment arms: 120 or 240mg alicaforsen
or 4 g mesalazine enema, given once daily for a total of 6 weeks
(Miner et al., 2006). The aim of the study was to compare
the effects of alicaforsen enema administration to standard
mesalazine enema therapy. The primary endpoint was DAI
reduction at week 6. No significant differences were highlighted
between the treatment arms. The mean percentage reduction of
the DAI score from baseline was 50% for the group treated with
the mesalazine enema and 40% and 41% for the group treated
with 120 and 240mg of the alicaforsen enema (p= 0.27 and 0.32,
respectively). Despite the failed difference regarding the primary
endpoint, in the therapeutic arms of the alicaforsen enema the
Frontiers in Pharmacology | www.frontiersin.org 3 April 2019 | Volume 10 | Article 314
Scarozza et al. Oligonucleotide Based Therapies
maintenance of clinical response was longer (128 and 146 days,
respectively) in comparison to the mesalazine arm (54 days)
(Miner et al., 2006).Moreover, the highest rate ofmucosal healing
in the 240mg alicaforsen group was evidenced at week 10 and
was achieved by 24% of patients; in the mesalazine arm it was
achieved by 17% of patients and was evidenced at week 3 and
6 (p = 0.06) (Miner et al., 2006). These two studies indicated a
possible modest durable effect of alicaforsen enema application
and sustained maintenance of clinical response, but nevertheless
non-significance regarding the primary endpoint.
A post-hocmeta-analysis focused on the results of four phase 2
clinical studies and investigated the overall efficacy of alicaforsen
enema administration in the treatment of patients with active
left-sided UC and pancolitis. The authors considered for the
meta-analysis three different subgroups of patients: the subgroup
with distal UC with active inflammation and disease extension
from 5–40 cm; the subgroup with moderate or severe disease
regardless of the extension of disease and the subgroup with both
distal colitis and moderate/severe inflammation. The authors
considered for the analysis the following treatment patterns:
240mg alicaforsen enema once daily for a duration of 6 weeks;
4 g mesalazine enema once daily for 6 weeks or placebo. The
higher efficacy (measured as mean percentage reduction in the
DAI score) of alicaforsen over placebo was statistically significant
at week 6 (51.4 vs. 27.1%; p = 0.004) and week 10 (51 vs.
24.7%; p = 0.014) in patients with distal disease. At week 30,
alicaforsen enema application did not demonstrate a significant
effect of maintenance of clinical response in comparison to
placebo therapy (Vegter et al., 2013).
In the meta-analysis, a similar clinical efficacy (measured as
mean percentage reduction in the DAI score) at week 6 and
10 was evidenced between alicaforsen and mesalazine enema
therapy (51.4 vs. 51.3% at week 6 and 51 vs. 41.6% at week 10).
However, the efficacy of alicaforsen enema was more durable
than that of mesalazine, after 6 weeks of treatment. At week
30 the efficacy (mean percentage reduction in the DAI score)
of alicaforsen enema application resulted to be 40.1%, while
the efficacy of mesalazine enema was 20.6% (p = 0.05) in the
treated patients. Similar results as for the subgroup with distal
UCwere found for the remaining two other subgroups of patients
(Vegter et al., 2013).
Despite the profound improvement in UC management with
biological drugs, a substantial proportion of patients require
surgical treatment with proctocolectomy and ileal-pouch-anal
anastomosis (IPAA) in the course of disease, in particular for
severe flares of active disease, refractory to available medical
therapies or due to the diagnosis of non-resectable colonic
dysplasia. Onset of acute or chronic pouchitis is one of the most
frequently occurring post-operative complications that patients
experience and almost half of them present with this kind
of problem within 5 years after the time of surgery (Tiainen
and Matikainen, 1999). Alicaforsen could represent a novel
therapeutic option for this hard to treat clinical problem, as
indicated by conducted studies.
A first open-label uncontrolled study conducted in 12 patients
affected by chronic pouchitis figured out a statistical significant
reduction of the Pouch-Disease-Activity-Index (PDAI), which
was 11.42 at baseline and 6.83 at week 6 (p= 0.001) and also of the
PDAI endoscopic sub-score at week 6, which was 3.75 at baseline
and 2.25 at week 6 (p= 0.0117) after daily topical administration
of alicaforsen at a dosage of 240mg for 6 weeks (Miner et al.,
2004; McConnell et al., 2009). A phase III randomized trial
conducted in patients affected by refractory pouchitis has been
recently completed (Fiorino et al., 2011; EPG Health, 2018).
The main findings regarding the above mentioned clinical
trials can be found in Table 1.
MONGERSEN
Immune homeostasis in the intestinal mucosa plays a
fundamental role in preventing inflammatory immune responses
in IBD (MacDonald and Monteleone, 2005; MacDonald et al.,
2011). One of the most important cytokines that mediate a
regulatory mucosal immune response is Transforming Growth
Factor β (TGFβ). This cytokine has been implicated in the
function of regulatory T (T reg) cells that mediate suppression of
inflammatory responses, as evidenced in mice models of colitis
(Powrie et al., 1996). Different studies figured out a greater level
of regulatory T cells in the inflamed mucosa of IBD patients
than in healthy controls, thereby inducing subsequent studies
for the analysis of T reg cells in the tissue of IBD patients
(Monteleone et al., 2001).
A study conducted in mice models of colitis demonstrated
increased TGFβ levels in the inflamed tissue of colitic mice,
indicating that a blockade of TGFβ signaling transduction by
counter-regulatory proteins overexpressed during the active
state of inflammation might be involved to suppress its anti-
inflammatory function (Boirivant et al., 2006). This finding has
been the first step toward the discovery of Mothers against
decapentaplegic homolog 7 (Smad7) that has an inhibitory role
within the TGFβ signaling cascade. This intracellular signaling
molecule is an inhibitor of TGFβ signaling, as it can bind
to the TGFβ receptor thereby inhibiting phosphorylation of
downstream signaling molecules such as Smad2 and Smad3,
whose activation mediates TGFβ signal transduction.
First studies figured out a heightened expression of Smad7 in
themucosal intestinal compartment of IBD patients (Monteleone
et al., 2001). In contrast, high expression of phosphorylated
Smad3 was seen in the normal intestinal mucosa (Monteleone
et al., 2001). The same study showed an increased response of
intestinal mononuclear cells to TGFβ after the administration of
a Smad7 ASO, which restored the phosphorylation of Smad3.
These findings demonstrate that Smad7 blockade by a Smad7
ASO enabled TGFβ to inhibit the function of pro-inflammatory
intestinal cells.
A subsequent phase I open-label study of an ASO against
Smad7 (GED0301) was conducted in CD patients with
steroid-dependent/resistant disease. Fifteen CD patients were
randomized to receive one of the three treatment dosages of
oral GED0301 (40, 80, or 160mg) once daily for 7 consecutive
days. The drug was well-tolerated. Oral administration of
GED0301 (mongersen) led to the reduction of pro-inflammatory
C-C Chemokine Receptor 9 (CCR9)-positive T cells in
the bloodstream. This study showed a good safety and
tolerability profile of the studied substance (Monteleone
et al., 2012). Since TGFβ has been described to induce the
Frontiers in Pharmacology | www.frontiersin.org 4 April 2019 | Volume 10 | Article 314
Scarozza et al. Oligonucleotide Based Therapies
T
A
B
L
E
1
|
O
ve
rv
ie
w
o
f
c
lin
ic
a
ls
tu
d
ie
s
w
ith
a
lic
a
fo
rs
e
n
.
S
tu
d
y
d
ru
g
S
tu
d
y
P
h
a
s
e
S
tu
d
y
p
o
p
u
la
ti
o
n
S
tu
d
y
d
e
s
ig
n
C
o
h
o
rt
s
iz
e
D
ru
g
d
o
s
a
g
e
a
n
d
fr
e
q
u
e
n
c
y
o
f
d
o
s
e
s
P
ri
m
a
ry
e
n
d
p
o
in
t
R
e
s
u
lt
s
IS
IS
2
3
0
2
P
h
a
se
Is
a
fe
ty
a
n
d
p
h
a
rm
a
c
o
ki
n
e
tic
p
ro
fil
e
o
f
a
n
in
te
rc
e
llu
la
r
a
d
h
e
si
o
n
m
o
le
c
u
le
-1
a
n
tis
e
n
se
o
lig
o
d
e
o
xy
n
u
c
le
o
tid
e
(IS
IS
2
3
0
2
)
( G
lo
ve
r
e
t
a
l.,
1
9
9
7
)
P
h
a
se
1
H
e
a
lth
y
m
a
le
vo
lu
n
te
e
rs
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
4
4
m
a
le
vo
lu
n
te
e
rs
F
o
u
r
h
e
a
lth
y
m
a
le
vo
lu
n
te
e
rs
re
c
ru
ite
d
to
e
a
c
h
o
f
se
ve
n
si
n
g
le
-d
o
se
g
ro
u
p
s
(0
.0
6
,
0
.1
2
,
0
.2
4
,
0
.5
,
1
.0
,
1
.5
,
a
n
d
2
.0
m
g
/k
g
)
a
n
d
e
a
c
h
o
f
fo
u
r
m
u
lti
p
le
-d
o
se
g
ro
u
p
s
(0
.2
,
0
.5
,
1
.0
,
a
n
d
2
.0
m
g
/k
g
).
O
n
e
su
b
je
c
t
in
e
a
c
h
g
ro
u
p
w
a
s
a
llo
c
a
te
d
to
p
la
c
e
b
o
a
rm
.
T
h
e
d
ru
g
w
a
s
in
fu
se
d
in
tr
a
ve
n
o
u
sl
y
o
n
d
a
y
1
in
th
e
si
n
g
le
d
o
se
-g
ro
u
p
a
n
d
o
n
d
a
ys
1
,
3
,
5
,
a
n
d
7
in
th
e
m
u
lti
p
le
-d
o
se
g
ro
u
p
S
a
fe
ty
a
n
d
p
h
a
rm
a
c
o
ki
n
e
tic
p
ro
fil
e
o
f
th
e
d
ru
g
G
o
o
d
to
le
ra
b
ili
ty
to
th
e
d
ru
g
,
w
ith
re
p
ro
d
u
c
ib
ili
ty
o
f
p
la
sm
a
p
h
a
rm
a
c
o
ki
n
e
tic
s
IS
IS
2
3
0
2
D
o
se
ra
n
g
in
g
p
h
a
rm
a
c
o
ki
n
e
tic
tr
ia
lo
f
h
ig
h
-d
o
se
a
lic
a
fo
rs
e
n
(in
te
rc
e
llu
la
r
a
d
h
e
si
o
n
m
o
le
c
u
le
-1
a
n
tis
e
n
se
o
lig
o
d
e
o
xy
n
u
c
le
o
tid
e
)
(IS
IS
2
3
0
2
)
in
a
c
tiv
e
C
ro
h
n
’s
d
is
e
a
se
( Y
a
c
ys
h
yn
e
t
a
l.,
2
0
0
2
a
)
/
P
a
tie
n
ts
w
ith
a
c
tiv
e
C
D
(C
D
A
I≥
2
2
0
)
D
o
u
b
le
-b
lin
d
,
ra
n
d
o
m
iz
e
d
st
u
d
y
2
2
C
D
p
a
tie
n
ts
1
0
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
th
e
3
0
0
m
g
a
rm
,
1
0
to
th
e
3
5
0
m
g
a
rm
a
n
d
2
p
a
tie
n
ts
to
th
e
2
5
0
m
g
a
rm
.
T
h
e
d
ru
g
w
a
s
in
fu
se
d
in
tr
a
ve
n
o
u
sl
y
th
re
e
tim
e
s
a
w
e
e
k
fo
r
4
w
e
e
ks
C
lin
ic
a
lr
e
m
is
si
o
n
(C
D
A
I
≤
1
5
0
)
a
t
w
e
e
k
8
,
1
2
,
a
n
d
a
ft
e
r
6
m
o
n
th
s
In
th
e
in
te
n
tio
n
to
tr
e
a
t
(IT
T
)
p
o
p
u
la
tio
n
1
4
%
(3
/2
2
)
o
f
th
e
p
a
tie
n
ts
a
t
w
e
e
k
8
a
n
d
2
3
%
(5
/2
2
)
o
f
th
e
p
a
tie
n
ts
a
t
w
e
e
k
1
2
w
e
re
in
c
lin
ic
a
l
re
m
is
si
o
n
.
A
ft
e
r
6
m
o
n
th
s,
1
8
%
(4
/2
2
)
o
f
th
e
IT
T
p
a
tie
n
ts
w
e
re
in
c
lin
ic
a
l
re
m
is
si
o
n
.
T
h
e
e
ffi
c
a
c
y
w
a
s
e
q
u
iv
a
le
n
t
w
ith
a
ll
th
e
th
re
e
d
o
se
s
u
se
d
IS
IS
2
3
0
2
A
p
la
c
e
b
o
-c
o
n
tr
o
lle
d
tr
ia
lo
f
IC
A
M
-1
a
n
tis
e
n
se
o
lig
o
n
u
c
le
o
tid
e
in
th
e
tr
e
a
tm
e
n
t
o
f
C
ro
h
n
’s
d
is
e
a
se
( Y
a
c
ys
h
yn
e
t
a
l.,
1
9
9
8
)
/
P
a
tie
n
ts
w
ith
a
c
tiv
e
m
o
d
e
ra
te
C
D
(C
D
A
I
2
2
0
–3
5
0
)
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
2
0
C
D
p
a
tie
n
ts
T
h
e
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
(3
:1
,
IS
IS
2
3
0
2
to
p
la
c
e
b
o
).
T
h
e
d
ru
g
w
a
s
in
fu
se
d
in
tr
a
ve
n
o
u
sl
y
a
t
a
d
o
sa
g
e
o
f
0
.5
,
1
,
o
r
2
m
g
/k
g
a
n
d
w
a
s
a
d
m
in
is
te
re
d
in
1
3
d
o
se
s
o
ve
r
2
6
d
a
ys
A
ss
e
ss
m
e
n
t
o
f
to
le
ra
b
ili
ty
,
p
h
a
rm
a
c
o
lo
g
y
a
n
d
e
ffi
c
a
c
y
o
f
th
e
d
ru
g
in
st
e
ro
id
-d
e
p
e
n
d
e
n
t
C
D
C
lin
ic
a
lr
e
m
is
si
o
n
w
a
s
fig
u
re
d
o
u
t
in
4
7
%
(7
/1
5
)
o
f
th
e
p
a
tie
n
ts
tr
e
a
te
d
w
ith
th
e
d
ru
g
a
n
d
in
2
0
%
(1
/5
)
o
f
th
o
se
tr
e
a
te
d
w
ith
p
la
c
e
b
o
a
ft
e
r
2
6
d
a
ys
fr
o
m
th
e
st
a
rt
o
f
th
e
th
e
ra
p
y.
A
ft
e
r
6
m
o
n
th
s
5
o
f
th
e
7
p
a
tie
n
ts
tr
e
a
te
d
w
ith
th
e
d
ru
g
m
a
in
ta
in
e
d
re
m
is
si
o
n
.
T
h
e
d
ru
g
w
a
s
c
o
rr
e
la
te
d
to
a
g
o
o
d
p
ro
fil
e
o
f
sa
fe
ty
IS
IS
2
3
0
2
E
ffi
c
a
c
y
o
f
su
b
c
u
ta
n
e
o
u
s
a
n
tis
e
n
se
IC
A
M
-1
tr
e
a
tm
e
n
t
o
f
c
h
ro
n
ic
a
c
tiv
e
C
ro
h
n
’s
d
is
e
a
se
( S
c
h
re
ib
e
r
e
t
a
l.,
2
0
0
1
)
/
P
a
tie
n
ts
w
ith
st
e
ro
id
-
re
fr
a
c
to
ry
C
D
(C
D
A
I
2
0
0
–4
0
0
)
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
7
5
C
D
p
a
tie
n
ts
7
5
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
4
tr
e
a
tm
e
n
t
a
rm
s
a
n
d
a
p
la
c
e
b
o
g
ro
u
p
.
1
4
p
a
tie
n
ts
re
c
e
iv
e
d
tr
e
a
tm
e
n
t
fo
r
2
d
a
ys
,
1
7
p
a
tie
n
ts
fo
r
1
w
e
e
k,
1
5
p
a
tie
n
ts
fo
r
2
w
e
e
ks
a
n
d
1
4
p
a
tie
n
ts
fo
r
4
w
e
e
ks
.
1
5
p
a
tie
n
ts
re
c
e
iv
e
d
p
la
c
e
b
o
.
T
h
e
d
ru
g
w
a
s
a
d
m
in
is
te
re
d
su
b
c
u
ta
n
e
o
u
sl
y
a
t
a
d
o
sa
g
e
o
f
0
.5
m
g
/k
g
C
o
m
p
le
te
c
lin
ic
a
l
re
m
is
si
o
n
(C
D
A
I<
1
5
0
w
ith
d
is
c
o
n
tin
u
a
tio
n
o
f
st
e
ro
id
s)
a
t
w
e
e
k
1
4
C
lin
ic
a
lr
e
m
is
si
o
n
w
a
s
re
a
c
h
e
d
b
y
1
8
.3
%
o
f
tr
e
a
te
d
p
a
tie
n
ts
a
n
d
b
y
2
0
%
o
f
th
o
se
tr
e
a
te
d
w
ith
p
la
c
e
b
o
a
t
th
e
w
e
e
k
1
4
.
N
o
d
iff
e
re
n
c
e
in
c
lin
ic
a
l
re
m
is
si
o
n
b
e
tw
e
e
n
th
e
d
ru
g
a
n
d
p
la
c
e
b
o
w
a
s
e
vi
d
e
n
c
e
d
(C
o
n
ti
n
u
e
d
)
Frontiers in Pharmacology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 314
Scarozza et al. Oligonucleotide Based Therapies
T
A
B
L
E
1
|
C
o
n
tin
u
e
d
S
tu
d
y
d
ru
g
S
tu
d
y
P
h
a
s
e
S
tu
d
y
p
o
p
u
la
ti
o
n
S
tu
d
y
d
e
s
ig
n
C
o
h
o
rt
s
iz
e
D
ru
g
d
o
s
a
g
e
a
n
d
fr
e
q
u
e
n
c
y
o
f
d
o
s
e
s
P
ri
m
a
ry
e
n
d
p
o
in
t
R
e
s
u
lt
s
IS
IS
2
3
0
2
D
o
u
b
le
b
lin
d
,
p
la
c
e
b
o
c
o
n
tr
o
lle
d
tr
ia
l
o
f
th
e
re
m
is
si
o
n
in
d
u
c
in
g
a
n
d
st
e
ro
id
sp
a
rin
g
p
ro
p
e
rt
ie
s
o
f
a
n
IC
A
M
-1
a
n
tis
e
n
se
o
lig
o
d
e
o
xy
n
u
c
le
o
tid
e
,
a
lic
a
fo
rs
e
n
(IS
IS
2
3
0
2
),
in
a
c
tiv
e
st
e
ro
id
d
e
p
e
n
d
e
n
t
C
ro
h
n
’s
d
is
e
a
se
( Y
a
c
ys
h
yn
e
t
a
l.,
2
0
0
2
b
)
/
S
te
ro
id
d
e
p
e
n
d
e
n
t
C
D
p
a
tie
n
ts
w
ith
a
c
tiv
e
d
is
e
a
se
(C
D
A
I
2
0
0
–3
5
0
)
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
2
9
9
C
D
p
a
tie
n
ts
T
h
e
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
in
to
th
re
e
g
ro
u
p
s:
IS
IS
2
3
0
2
a
t
a
d
o
sa
g
e
o
f
2
m
g
/k
g
in
tr
a
ve
n
o
u
sl
y
th
re
e
tim
e
s
a
w
e
e
k
fo
r
2
w
e
e
ks
,
IS
IS
2
3
0
2
a
t
th
e
sa
m
e
d
o
sa
g
e
a
n
d
w
ith
th
e
sa
m
e
fr
e
q
u
e
n
c
y
b
u
t
fo
r
4
w
e
e
ks
a
n
d
p
la
c
e
b
o
S
te
ro
id
fr
e
e
re
m
is
si
o
n
w
ith
a
C
D
A
I<
1
5
0
a
t
th
e
e
n
d
o
f
w
e
e
k
1
4
S
te
ro
id
fr
e
e
re
m
is
si
o
n
a
t
w
e
e
k
1
4
w
a
s
2
0
.2
%
in
th
e
g
ro
u
p
tr
e
a
te
d
fo
r
2
w
e
e
ks
,
2
1
.2
%
in
th
e
g
ro
u
p
tr
e
a
te
d
fo
r
4
w
e
e
ks
a
n
d
1
8
.8
%
in
p
la
c
e
b
o
g
ro
u
p
.
N
o
d
iff
e
re
n
c
e
in
c
lin
ic
a
l
re
m
is
si
o
n
b
e
tw
e
e
n
th
e
d
ru
g
a
n
d
p
la
c
e
b
o
w
a
s
e
vi
d
e
n
c
e
d
IS
IS
2
3
0
2
(A
lic
a
fo
rs
e
n
)
A
ra
n
d
o
m
iz
e
d
,
d
o
u
b
le
-m
a
sk
e
d
,
p
la
c
e
b
o
-c
o
n
tr
o
lle
d
st
u
d
y
o
f
a
lic
a
fo
rs
e
n
,
a
n
a
n
tis
e
n
se
in
h
ib
ito
r
o
f
in
te
rc
e
llu
la
r
a
d
h
e
si
o
n
m
o
le
c
u
le
1
,
fo
r
th
e
tr
e
a
tm
e
n
t
o
f
su
b
je
c
ts
w
ith
a
c
tiv
e
C
ro
h
n
’s
d
is
e
a
se
( Y
a
c
ys
h
yn
e
t
a
l.,
2
0
0
7
)
P
h
a
se
3
P
a
tie
n
ts
w
ith
a
c
tiv
e
C
D
(C
D
A
I
2
2
0
–4
0
0
)
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
3
3
1
C
D
p
a
tie
n
ts
2
2
1
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
th
e
st
u
d
y
d
ru
g
a
t
a
d
o
sa
g
e
o
f
1
0
0
m
g
a
t
th
e
fir
st
in
fu
si
o
n
a
n
d
fo
r
th
e
o
th
e
r
1
1
in
fu
si
o
n
s
a
t
a
d
o
sa
g
e
o
f
3
0
0
m
g
(p
a
tie
n
ts
w
e
ig
h
in
g
m
o
re
th
a
n
5
0
kg
)
o
r
2
0
0
m
g
(p
a
tie
n
ts
w
e
ig
h
in
g
3
6
–5
0
kg
).
T
h
e
d
ru
g
w
a
s
a
d
m
in
is
te
re
d
in
tr
a
ve
n
o
u
sl
y
3
tim
e
s
a
w
e
e
k
fo
r
4
w
e
e
ks
.
1
1
0
p
a
tie
n
ts
w
e
re
e
n
ro
lle
d
in
p
la
c
e
b
o
a
rm
C
lin
ic
a
lr
e
m
is
si
o
n
a
t
w
e
e
k
1
2
N
o
st
a
tis
tic
a
ld
iff
e
re
n
c
e
b
e
tw
e
e
n
th
e
st
u
d
y
d
ru
g
a
n
d
p
la
c
e
b
o
fo
r
c
lin
ic
a
l
re
m
is
si
o
n
a
t
w
e
e
k
1
2
(3
3
.9
%
in
th
e
d
ru
g
a
n
d
3
4
.5
%
in
th
e
p
la
c
e
b
o
a
rm
)
IS
IS
2
3
0
2
(A
lic
a
fo
rs
e
n
)
A
ra
n
d
o
m
iz
e
d
,
c
o
n
tr
o
lle
d
,
d
o
u
b
le
b
lin
d
,
e
sc
a
la
tin
g
d
o
se
st
u
d
y
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
in
a
c
tiv
e
u
lc
e
ra
tiv
e
c
o
lit
is
(v
a
n
D
e
ve
n
te
r
e
t
a
l.,
2
0
0
4
)
/
P
a
tie
n
ts
w
ith
a
c
tiv
e
d
is
ta
l
U
C
(D
A
I4
–1
0
)
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
4
0
U
C
p
a
tie
n
ts
T
h
e
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
th
e
a
lic
a
fo
rs
e
n
e
n
e
m
a
a
d
m
in
is
tr
a
tio
n
a
t
fo
u
r
d
iff
e
re
n
t
d
o
sa
g
e
s
(0
.1
,
0
.5
,
2
,
o
r
4
m
g
/m
l)
o
r
to
p
la
c
e
b
o
.
E
a
c
h
p
a
tie
n
t
re
c
e
iv
e
d
a
lic
a
fo
rs
e
n
e
n
e
m
a
o
n
c
e
d
a
ily
fo
r
2
8
d
a
ys
S
a
fe
ty
a
n
d
e
ffi
c
a
c
y
o
f
th
e
d
ru
g
e
n
e
m
a
a
ft
e
r
1
,
3
,
a
n
d
6
m
o
n
th
s
A
t
1
m
o
n
th
a
lic
a
fo
rs
e
n
e
n
e
m
a
(4
m
g
/m
l)
w
a
s
c
o
rr
e
la
te
d
w
ith
7
0
%
o
f
im
p
ro
ve
d
d
is
e
a
se
a
c
tiv
ity
in
d
e
x
c
o
m
p
a
re
d
to
2
8
%
w
ith
p
la
c
e
b
o
,
w
ith
st
a
tis
tic
a
l
si
g
n
ifi
c
a
n
t
d
iff
e
re
n
c
e
.
T
h
is
p
o
si
tiv
e
o
u
tc
o
m
e
w
a
s
e
vi
d
e
n
c
e
d
a
ls
o
a
ft
e
r
3
a
n
d
6
m
o
n
th
s
IS
IS
2
3
0
2
(A
lic
a
fo
rs
e
n
)
A
P
h
a
se
II
d
o
se
ra
n
g
in
g
,
d
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-c
o
n
tr
o
lle
d
st
u
d
y
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
in
su
b
je
c
ts
w
ith
a
c
u
te
e
xa
c
e
rb
a
tio
n
o
f
m
ild
to
m
o
d
e
ra
te
le
ft
-s
id
e
d
u
lc
e
ra
tiv
e
c
o
lit
is
(v
a
n
D
e
ve
n
te
r
e
t
a
l.,
2
0
0
6
)
P
h
a
se
2
P
a
tie
n
ts
w
ith
a
c
tiv
e
d
is
ta
l
U
C
(D
A
I
4
–1
0
)
w
ith
d
is
e
a
se
fla
re
D
o
u
b
le
-b
lin
d
,
p
la
c
e
b
o
-
c
o
n
tr
o
lle
d
st
u
d
y
1
2
0
U
C
p
a
tie
n
ts
T
h
e
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
fiv
e
tr
e
a
tm
e
n
t
a
rm
s:
p
la
c
e
b
o
,
a
lic
a
fo
rs
e
n
e
n
e
m
a
a
t
a
d
o
sa
g
e
o
f
1
2
0
m
g
d
a
ily
fo
r
1
0
d
a
ys
a
n
d
th
e
n
e
ve
ry
o
th
e
r
d
a
y,
2
4
0
m
g
e
ve
ry
o
th
e
r
d
a
y,
2
4
0
m
g
d
a
ily
fo
r
1
0
d
a
ys
a
n
d
th
e
n
e
ve
ry
o
th
e
r
d
a
y,
2
4
0
m
g
d
a
ily
D
is
e
a
se
A
c
tiv
ity
In
d
e
x
a
t
w
e
e
k
6
N
o
si
g
n
ifi
c
a
n
t
d
iff
e
re
n
c
e
b
e
tw
e
e
n
a
lic
a
fo
rs
e
n
a
n
d
p
la
c
e
b
o
e
n
e
m
a
w
a
s
e
vi
d
e
n
c
e
d
a
t
w
e
e
k
6
,
b
u
t
th
e
a
rm
o
f
a
lic
a
fo
rs
e
n
(2
4
0
m
g
w
ith
d
a
ily
a
d
m
in
is
tr
a
tio
n
)
e
vi
d
e
n
c
e
d
a
st
a
tis
tic
a
lb
e
n
e
fit
o
ve
r
p
la
c
e
b
o
fo
r
p
ro
lo
n
g
e
d
re
d
u
c
tio
n
o
f
D
A
I
fr
o
m
th
e
w
e
e
k
1
8
to
w
e
e
k
3
0
(C
o
n
ti
n
u
e
d
)
Frontiers in Pharmacology | www.frontiersin.org 6 April 2019 | Volume 10 | Article 314
Scarozza et al. Oligonucleotide Based Therapies
T
A
B
L
E
1
|
C
o
n
tin
u
e
d
S
tu
d
y
d
ru
g
S
tu
d
y
P
h
a
s
e
S
tu
d
y
p
o
p
u
la
ti
o
n
S
tu
d
y
d
e
s
ig
n
C
o
h
o
rt
s
iz
e
D
ru
g
d
o
s
a
g
e
a
n
d
fr
e
q
u
e
n
c
y
o
f
d
o
s
e
s
P
ri
m
a
ry
e
n
d
p
o
in
t
R
e
s
u
lt
s
IS
IS
2
3
0
2
(A
lic
a
fo
rs
e
n
)
S
a
fe
ty
a
n
d
e
ffi
c
a
c
y
o
f
tw
o
d
o
se
fo
rm
u
la
tio
n
s
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
c
o
m
p
a
re
d
w
ith
m
e
sa
la
zi
n
e
e
n
e
m
a
fo
r
tr
e
a
tm
e
n
t
o
f
m
ild
to
m
o
d
e
ra
te
le
ft
-s
id
e
d
u
lc
e
ra
tiv
e
c
o
lit
is
:
a
ra
n
d
o
m
iz
e
d
,
d
o
u
b
le
-b
lin
d
,
a
c
tiv
e
-c
o
n
tr
o
lle
d
tr
ia
l(
M
in
e
r
e
t
a
l.,
2
0
0
6
)
/
P
a
tie
n
ts
w
ith
a
c
tiv
e
U
C
(D
A
I4
–1
0
)
D
o
u
b
le
-b
lin
d
,
a
c
tiv
e
-
c
o
n
tr
o
lle
d
st
u
d
y
1
5
9
U
C
p
a
tie
n
ts
T
h
e
p
a
tie
n
ts
w
e
re
ra
n
d
o
m
iz
e
d
to
a
lic
a
fo
rs
e
n
e
n
e
m
a
a
t
a
d
o
sa
g
e
o
f
1
2
0
m
g
o
r
2
4
0
m
g
o
r
to
m
e
sa
la
zi
n
e
e
n
e
m
a
a
t
a
d
o
sa
g
e
o
f
4
g
.
T
h
e
e
n
e
m
a
w
a
s
a
d
m
in
is
te
re
d
d
a
ily
fo
r
6
w
e
e
ks
D
A
Ia
t
w
e
e
k
6
re
la
tiv
e
to
b
a
se
lin
e
N
o
d
iff
e
re
n
c
e
in
re
d
u
c
in
g
c
lin
ic
a
la
c
tiv
ity
w
a
s
e
vi
d
e
n
c
e
d
b
e
tw
e
e
n
th
e
tr
e
a
tm
e
n
t
st
ra
te
g
ie
s
a
t
w
e
e
k
6
,
b
u
t
a
lic
a
fo
rs
e
n
e
n
e
m
a
e
vi
d
e
n
c
e
d
m
o
re
p
ro
lo
n
g
e
d
re
sp
o
n
se
th
a
n
m
e
sa
la
zi
n
e
e
n
e
m
a
IS
IS
2
3
0
2
(A
lic
a
fo
rs
e
n
)
A
n
e
n
e
m
a
fo
rm
u
la
tio
n
o
f
a
lic
a
fo
rs
e
n
,
a
n
a
n
tis
e
n
se
in
h
ib
ito
r
o
f
in
te
rc
e
llu
la
r
a
d
h
e
si
o
n
m
o
le
c
u
le
-1
,
in
th
e
tr
e
a
tm
e
n
t
o
f
c
h
ro
n
ic
,
u
n
re
m
itt
in
g
p
o
u
c
h
iti
s
(M
in
e
r
e
t
a
l.,
2
0
0
4
)
/
P
a
tie
n
ts
w
ith
c
h
ro
n
ic
,
u
n
re
m
itt
in
g
p
o
u
c
h
iti
s
w
ith
a
P
o
u
c
h
iti
s
D
is
e
a
se
A
c
tiv
ity
In
d
e
x
(P
D
A
I)
sc
o
re
o
f
≥
7
O
p
e
n
-l
a
b
e
l,
u
n
c
o
n
tr
o
lle
d
st
u
d
y
1
2
p
a
tie
n
ts
a
ff
e
c
te
d
b
y
c
h
ro
n
ic
u
n
re
m
itt
in
g
p
o
u
c
h
iti
s
T
h
e
p
a
tie
n
ts
re
c
e
iv
e
d
d
a
ily
a
d
m
in
is
tr
a
tio
n
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
a
t
a
d
o
sa
g
e
o
f
2
4
0
m
g
fo
r
6
w
e
e
ks
E
ffi
c
a
c
y
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
in
th
e
tr
e
a
tm
e
n
t
o
f
c
h
ro
n
ic
u
n
re
m
itt
in
g
p
o
u
c
h
iti
s
A
si
g
n
ifi
c
a
n
t
b
e
n
e
fit
o
f
a
lic
a
fo
rs
e
n
e
n
e
m
a
w
a
s
e
vi
d
e
n
c
e
d
a
t
w
e
e
k
6
.
T
h
e
P
D
A
I
sc
o
re
re
su
lte
d
to
b
e
6
.8
3
a
t
w
e
e
k
6
c
o
m
p
a
re
d
to
1
1
.4
2
a
t
b
a
se
lin
e
.
T
h
is
b
e
n
e
fit
w
a
s
e
vi
d
e
n
c
e
d
a
ls
o
fo
r
im
p
ro
ve
m
e
n
t
o
f
e
n
d
o
sc
o
p
ic
a
c
tiv
ity
C
D
,
C
ro
h
n
’s
d
is
e
a
s
e
;
U
C
,
u
lc
e
ra
ti
ve
c
o
lit
is
;
C
D
A
I,
C
ro
h
n
’s
d
is
e
a
s
e
A
c
ti
vi
ty
In
d
e
x;
D
A
I,
D
is
e
a
s
e
A
c
ti
vi
ty
In
d
e
x;
P
D
A
I,
P
o
u
c
h
it
is
D
is
e
a
s
e
A
c
ti
vi
ty
In
d
e
x;
IC
A
M
1
,
In
te
rc
e
llu
la
r
C
e
ll
A
d
h
e
s
io
n
M
o
le
c
u
le
-1
;
/,
p
h
a
s
e
in
d
ic
a
ti
o
n
n
o
t
fo
u
n
d
.
profibrogenetic response of fibroblasts, patients were monitored
for 6 months with intestinal ultrasonography, not showing
signs of intestinal stenosis. Moreover, half of the patients
maintained remission during the 6 months follow up period
(Zorzi et al., 2012).
Afterwards, a randomized, double-blind, phase 2 study
was conducted in CD patients with inflammatory lesions
in the terminal ileum and/or right colon, with steroid-
dependence/resistance, randomized to three different daily oral
drug doses (10, 40, or 160mg of mongersen or placebo) for 2
weeks. The primary outcome was clinical remission at day 15,
with maintenance of remission for at least 2 weeks. Clinical
remission was not significantly different between the patients in
the 10mg mongersen group and placebo (12 vs. 10%; p = N.S.);
however clinical remission was reached by 55% and 65% of
patients in the 40 and 160mg mongersen group, as compared to
10% in the placebo group (p < 0.001). The drug showed a good
safety and tolerability profile (Monteleone et al., 2015).
A following study demonstrated efficacy of GED0301 in
inducing both clinical and endoscopic response in a study
group of 63CD patients. The patients were randomized to three
treatment groups (4, 8, or 12 weeks of treatment with oral GED-
0301 at a dose of 160 mg/day). 37% of patients had an endoscopic
response, defined as≥25% reduction in Simple Endoscopic Score
for Crohn’s disease (SES-CD), at week 12, with a substantial
proportion of patients in clinical remission at the same time
point (32% in the group of 4 weeks of treatment, 35 and 48%,
respectively in the group of 8 and 12 weeks of treatment)
(Feagan et al., 2018). This study however lacked a placebo
control group.
Despite these promising results, a recently conducted phase
3 study was stopped following the finding of non-effectiveness
of the studied drug. No safety findings were reported (Bevivino
et al., 2018; White et al., 2018).
The main findings regarding the above mentioned clinical
trials can be found in Table 2.
NFkB ASO
Preclinical studies, conducted in murine models of colitis,
demonstrated the efficacy of an ASO against the p65 subunit
of the transcription factor Nuclear Factor Kappa B (NFkB)
(Neurath et al., 1996; Murano et al., 2000). This transcription
factor mediates a key role in the pro-inflammatory response of
immune-mediated disorders (Zhang et al., 2017).
A preclinical study evidenced an upregulation of p65
expression in macrophages located in the Lamina propria of
patients affected by CD. The authors demonstrated the efficacy of
a human p65 ASO to reduce the production of pro-inflammatory
cytokines by these cells (Neurath et al., 1996). Another study
conducted in a murine model of colitis demonstrated a down-
regulation of chronic inflammation- induced intestinal fibrosis by
the p65 ASO (Lawrance et al., 2003).
Despite these promising results, no clinical study has been
published so far regarding the use of this therapeutic strategy in
IBD patients (Marafini and Monteleone, 2018).
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COBITOLIMOD
Cobitolimod (formerly referred to as DIMS0150) is a single-
stranded oligonucleotide that is recognized by the Toll-like
Receptor 9 (TLR9) and represents a possible promising novel
therapy for UC patients. The altered response of intestinal
immune cells to the commensal bacterial flora has been
considered to be one of the pivotal pathogenic mechanisms in
UC (Strober et al., 2007). The protective immune cell response
plays the counterpart action against the over activation of the
mucosal immune system (Neurath, 2014). Toll-like receptors
(TLRs) belong to pattern recognition receptors (PRRs), which
mediate the recognition process of self-antigens from foreign-
antigens by the host. These receptors can recognize the pathogen
associated molecular patterns (PAMPs) and are implicated in
the first defensive innate immune response against luminal
pathogens, but can also induce mechanisms of cellular and
mucosal repair (Lee et al., 2006). TLR9 is a member of the TLR
family and recognizes bacterial DNA, but also viral DNA (e.g.,
Cytomegalovirus DNA). This receptor in particular recognizes
bacterial Cytosine Guanine (CpG) dinucleotides motifs
(Hemmi et al., 2000).
A study in the murine model of Salmonella typhimurium
infection figured out that the activation of TLR9 maintained
the homeostasis of intestinal mucosal cells, demonstrating
that disruption of TLR9 signaling could result in augmented
inflammation and worsening of intestinal injury (Li et al., 2017).
Cobitolimod is a 19 base single-strand oligonucleotide which
mimics bacterial DNA as its CpG dinucleotide sequences are
recognized by the TLR9 expressed by different immune cells,
thereby mediating anti-inflammatory effects. In preclinical
studies in murine models of colitis, administration of the TLR9
oligonucleotide agonist suppressed the severity of colitis in
RAG-/- mice. The type I Interferon (IFN α/β) was induced by
TLR9 activation and mediated anti-inflammatory responses
(Katakura et al., 2005). In another preclinical study conducted
in the experimental DSS model and spontaneous colitis
mice, administration of CpG oligonucleotides improved
clinical, biochemical and histologic activity of colonic
inflammation (Rachmilewitz et al., 2002).
A study published in 2013 considered the possible efficacy
of DIMS0150 in treating UC patients who had been considered
as treatment failures with indication for colectomy. Seven
patients received a single dose of topical DIMS0150 (30mg)
and one patient three doses with an interval of 4 weeks in
between. The study drug was applied during colonoscopy with
a spray catheter in the upper descending colon or the transverse
colon. Efficacy was recorded as an improvement of the DAI
score and of endoscopic and histological activity at week 12.
Clinical response was found in all patients 1 week after single
endoscopic administration of the drug. After 12 weeks, 82%
of patients had a clinical response while 71% were in clinical
remission. In the 2-year follow up one patient needed colectomy
(Musch et al., 2013).
A non-interventional pilot study analyzed the transcripts
of 34 steroid response genes by polymerase chain reaction
(PCR) in the blood derived peripheral mononuclear cells
(PBMCs) of steroid refractory UC patients, after their
incubation with DIMS0150 (25 or 100µM) in the presence
of Dexamethasone. The authors evidenced that addition
of DIMS0150 to steroid treatment produced a significant
enhancement of mRNA levels of three steroid response genes
(CD163, TSP-1, and IL-1RII) and suggested to consider these
genes as potential biomarkers of response to the study drug.
This study highlighted the potential effect of DIMS0150 to
restore steroid sensitivity in steroid refractory UC patients
(Kuznetsov et al., 2014).
After these findings a randomized, double-blind, placebo-
controlled trial (COLLECT study) was conducted in 131 patients
affected by moderate to severe UC. Patients were randomized to
receive two topical endoscopic administrations of cobitolimod
(DIMS0150) at a dosage of 30mg at baseline and week 4 or
respective placebo application. The administration was done
proximally to the site of mucosal inflammation, or in the
transverse colon in the event of pancolitis, using a spray catheter
during endoscopy (Atreya et al., 2016). There was no statistical
difference in the primary endpoint clinical remission, defined as
a CAI score of ≤4 at week 12, which was recorded in 44.4% of
cobitolimod treated patients and in 46.5% of those treated with
placebo (Atreya et al., 2016). However, symptomatic remission,
which was defined as the absence of blood in stool and a weekly
frequency of <35 stools, was shown in a larger proportion of
patients treated with the drug compared to those treated with
placebo (32.1% in the cobitolimod group vs. 14% in the placebo
group at week 4 (p= 0.02) and 44.4 vs. 27.9%, respectively at week
8 (p= 0.06).Mucosal healing at week 4 was also achieved bymore
cobitolimod treated patients compared to the placebo group,
but missed statistical significance (34.6 vs. 18.6%; p = 0.09).
Histological improvement, defined as a Geboes score of 0–2,
was evident in 30.9% of the cobitolimod treated vs. 9.3% of
the placebo treated patients (p = 0.007). The combination of
clinical and endoscopic remission could be observed in 21% of
cobitolimod treated patients vs. 4.7% of patients on placebo (p=
0.021) at week 4 (Atreya et al., 2016).
A recent post-hoc analysis, based on data from the COLLECT
study, has shown that the clinical efficacy of the drug is
significant if patient-reported-outcomes (PRO) were considered,
as the investigated outcome measure. Symptomatic remission
was studied in 104 patients based on their e-diary records and
was defined as the absence of blood in stool and a mean daily
stool frequency <4 (Atreya et al., 2018). Symptomatic remission
was found at week 4 in 17.1% of patients treated with cobitolimod
compared to 5.9% of patients treated with placebo (p= 0.13) and,
respectively, in 35.7 and 17.6% (p = 0.07) at week 8 and in 38.6
and 17.6% (p= 0.04) at week 12 (Atreya et al., 2018).
BL7040 (Monarsen) is an orally applied oligonucleotide that
modulates the TLR9 and it was investigated in a prospective
multicenter phase 2 study in patients with moderately active UC
at doses of 12mg once daily for 3 weeks followed by 40mg once
daily for 2 weeks. The primary endpoint was the proportion of
patients with clinical response at the end of 5 weeks of treatment.
Clinical response was defined by a decrease of at least three points
and 30 % reduction of the Mayo score compared to baseline. Half
of the patients (8/16) achieved clinical response at the end of the
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course of treatment, with a good tolerability profile of the drug
(Dotan et al., 2016).
Altogether, agonists of the Toll-like receptor-9 appeared safe
and well-tolerated in moderate to severe UC patients and
could represent a novel promising therapeutic option for the
management of UC patients.
Currently, a phase 2 study (CONDUCT) of different doses
and different administration intervals of cobitolimod in an
enema formulation is tested in patients affected by moderate to
severe UC1.
The main findings regarding the above mentioned clinical
trials can be found in Table 3.
GATA3 DNAzyme
The adaptive immune response and inappropriate production of
pro-inflammatory cytokines have an important pathogenic role
in IBD pathogenesis. CD is characterized by a prevalence of
T helper 1 (Th1) cytokines such as Interferon gamma (IFNγ)
and TNF, whereas UC is marked by a of more Th2 oriented
cytokine profile, characterized by IL4, IL5, and IL13 (Fuss et al.,
1996, 2004). However, these subsets of T cells are not the only
responsible cells for the inflammatory response in IBD. Th17 cells
are another lymphocyte subpopulation which has a major role
in intestinal inflammation in both CD and UC (Giuffrida et al.,
2018). A recent published review revealed also the important role
of other lymphocyte subsets in mucosal inflammation (Giuffrida
et al., 2018). Importantly, Th9 cells and IL9 have also been
described to play a pivotal role in the pathogenesis of UC
(Nalleweg et al., 2015; Weigmann and Neurath, 2017).
The GATA3 specific DNAzyme (SB010) is an oligonucleotide
which can mediate the cleavage of the mRNA of the transcription
factor GATA3 and its possible therapeutic usage in human
diseases was first investigated in patients affected by allergic
asthma. A double-blind placebo-controlled study randomized
40 patients, affected by allergic asthma, to receive 10mg of
SB010 or placebo. The drug was administered by inhalation
once daily for 28 days. Treatment with SB010 was found to be
effective in attenuating the late and early asthmatic responses to
allergen provocation; thereby the drug induced also a significant
reduction of IL5 blood levels (Krug et al., 2015).
The Th2 response is mediated by the transcription factor
GATA3, which has proven to be over-expressed in the colonic
mucosa of UC patients (Ho et al., 2009; Ohtani et al., 2010). This
transcription factor is not only linked to Th2 cell responses, but
also plays an important role in regulating the differentiation of
Th9 lymphocytes (Wan, 2014).
A study conducted with intestinal biopsies of UC patients as
well as murine models of colitis showed a correlation between
the expression of the transcription factor GATA3 and the
production of inflammatory Th2 and Th9 related cytokines
(Popp et al., 2016). Conditional GATA3 deficiency in T cells
prevented experimental colitis inmice. Intrarectal administration
of a GATA3 specific DNAzyme (hgd40) significantly ameliorated
colitis in oxazolone and 2,4,6-trinitrobenzene sulfonic acid
1ClinicalTrials.gov Identifier: NCT03178669.
(TNBS)-mediated colitis models (Popp et al., 2016). The authors
also demonstrated that the inhibition of GATA3 transcription by
hgd40 was able to ameliorate colitis also in TNF receptor (TNFR)
double-knockout mice. This result evidenced the efficacy of the
experimental drug in reducing colitis in mice, independently of
the presence of TNF (Popp et al., 2016).
These results underline the important role of GATA3 in the
inflammatory response in UC and suggest a possible future role
of the GATA3 DNAzyme in the therapy of UC patients.
A study of this novel drug as an enema formulation (SB012,
SECURE study) in patients with moderate to severe UC has
recently been completed (NCT02129439)2.
STNM01: AN OLIGONUCLEOTIDE
AGAINST CARBOHYDRATE
SULFOTRANSFERASE 15
IBD pathogenesis is not only connected to an active acute
and chronic inflammatory response but also to structural
damage, with matrix remodeling and tissue fibrosis, which
can take place independently of the inflammatory activity
(Suzuki and Yoneyama, 2017). Approximately one third of
patients with CD and 5% of those with UC are diagnosed
with fibrotic stenosis in the clinical course (Rieder et al., 2013;
de Bruyn et al., 2015). There are no specific therapies for the
management of fibrotic intestinal remodeling, induced by the
over activation of stromal cells during chronic inflammation.
Invasive treatment (endoscopic dilation and/or surgical
treatment) represent the inevitable final management step of
this complication.
Carbohydrate sulfotransferase 15 (CHST15) is an intracellular
enzyme that mediates the biosynthesis of sulfated matrix
glycosaminoglycans (GAG) which can induce fibrotic reactions
in IBD patients.
STNM01 is a novel double-strand RNA oligonucleotide that
selectively blocks the expression of CHST15 mRNA and can
inhibit the excessive production of glycosaminoglycans in the
colon by fibroblasts (Suzuki et al., 2016).
For this reason an endoscopic approach of drug delivery
through submucosal injection, to directly target the gut
lesion, was established in mice in 2016 (Suzuki et al., 2016).
CHST15 siRNA or negative control siRNA were endoscopically
administered by submucosal injection at day 6 in DSS-
mediated colitis models. The mice were sacrificed at day
19 to evaluate the effect of the experimental drug. CHST15
siRNA reduced CHST15 mRNA in the colon of treated mice
and significantly ameliorated endoscopic and histologic disease
activity (Suzuki et al., 2016).
A subsequent published randomized placebo-controlled trial
evaluated the safety of STNM01 in CD patients whose
mucosal ulcerative lesions were refractory to conventional
therapy. Eighteen CD patients were randomized to receive
a single endoscopic submucosal injection of STNM01 (2.5,
2https://www.clinicaltrials.gov/ct2/show/NCT02129439?term=NCT02129439&
rank=1
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25, or 250 nM) or placebo. Each dose was administered to
eight sites directly surrounding the biggest ulcerative lesion
evidenced by total colonoscopy. STNM01 was able to reduce
the segmental SES-CD score at day 30 when compared to
the placebo arm and was also able to induce a reduced
extension of fibrosis, documented by histological analyses.
The experimental drug also showed a good safety profile
(Suzuki et al., 2017).
A phase 2 clinical trial in UC patients affected by refractory
left-sided UC has recently been completed. The patients were
randomized to submucosal injections of STNM01 or placebo in
the last 35 cm of the colon.
The main findings regarding the above mentioned clinical
trials can be found in Table 4.
CONCLUSIONS
In this review, we focused on recent and past approaches to
test the therapeutic efficacy of oligonucleotide based therapies
in IBD.
The combining mechanistic mode of oligonucleotide based
therapeutics is a targeted action on specific pro-inflammatory
molecules, which are over activated in IBD patients and
contribute significantly to disease pathogenesis. The proposed
high selectivity of the agents is derived from its mode of
action, that aims to specifically block certain inflammatory
molecular patterns, without a general systemic effect on
other molecular targets. It would be important for each
oligonucleotide to present more data regarding its specific
mode of molecular action. Ideally, interaction with the
proposed molecular target should be presented. Overall, the
good tolerance and safety profile has allowed increasing
development of this therapeutic approach in IBD clinical research
and trials.
This new treatment strategy has the potential to address the
main concern of a safe long-term therapy for IBD patients.
Moreover, efficacious therapy could be prolonged as lasting
maintenance therapy, as there is no risk for secondary loss-of-
response due to the formation of anti-drug antibodies, which
is one of the main reasons for limited long-term efficacy of
biological drugs (Atreya and Neurath, 2018).
The above-mentioned properties and selectivity of
oligonucleotides could respond to the dire need for a safe
and efficacious long-term therapy. The numerous clinical trials
conducted so far have shown the possibility of oligonucleotide
treatment to match the target of safety and efficacy, but till
now no oligonucleotide based therapy has been approved for
clinical practice in the treatment of IBD patients and we still
await successful late-stage clinical studies that demonstrate
their efficaciousness.
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